Pacific Edge Limited · NZX:PEB
Pacific Edge — H1 FY2015 Earnings Presentation
9 slides from Pacific Edge's earnings presentation, Nov 28, 2014
Slide 1: FY15 Interim Results Presentation
FY15 Interim Results Presentation for the six months to 30 September 2014 28 November 2014 David Darling, CEO
Slide 2: First Half Growth Highlights
First Half Growth Highlights Strong revenue growth reflects the HY14 HY13 Change NZ$(000) NZ$(000) (%) Company’s positive commercial progress following the launch of its Revenue from ordinary activities 1,598 183 773 revolutionary bladder cancer Profit (loss) from ordinary activities (4,859) (4,971)
Slide 3: Vastly Improving Number of Cxbladder Tests Processed through Pacific Edge's Laboratories
Vastly Improving Number of Cxbladder Tests Processed through Pacific Edge’s Laboratories Increase of 93% from Q4 2014 to Q1 2015 Increase of 154% Q1 to Q2 2015 Test numbers not disclosed for commercial sensitivity reasons Combined laboratory through-put consists of both user study tests and commerci
Slide 4: United States Update
United States Update • Signed agreements with National Provider Networks – Multiplan, FedMed, ACPN, Stratos • Kaiser Permanente signed to a User Program for 2015 completion • User programmes in place with with a growing number of Large Urology Group practices • Commercial sales achieved and revenue
Slide 5: New Zealand and Other Jurisdictions: Update
New Zealand and Other Jurisdictions: Update • Successfully completed two validation studies with Waitemata and Canterbury District health boards with results supporting clinical study findings • Signed agreements with Urologists servicing BOP and Lakes District Health Boards • Continuing to work wit
Slide 6: Looking Forward
Looking Forward Objectives • Focusing on American healthcare market • Roll-out of Cxbladder Triage • Evaluating the roll-out to Sout East Asian markets in Singapore, Taiwan and Thailand • Developing new bladder cancer diagnostic tests • Aiding the launch of Cxbladder triage in New Zealand as a precu
Slide 7: Balance Sheet and Cash Flow 1H15
Balance Sheet and Cash Flow 1H15 Cash and equivalents of $14.7m as at 30 September 2014 Utilisation of $0.6m of cash in 1H15, including funding received from short term deposits Sufficient funds in place to continue development and growth strategy in existing markets in medium term Lean corporate st
Slide 8: New Product: Cxbladder Triage launches on time and to plan in December 2014
New Product: Cxbladder Triage launches on time and to plan in December 2014 Cxbladder Product suite Cxbladder (detect) Cxbladder (triage) Cxbladder (predict) Cxbladder (monitor) Expected launch Expected launch In-market 2014 2015 2016 This “family of bladder cancer products means Pacific Edge is abl
Slide 9: www.pacificedge.co.nz www.cxbladder.com www.pacificedgedx.com
www.pacificedge.co.nz www.cxbladder.com www.pacificedgedx.com David Darling Chief Executive Officer Pacific Edge Limited Cell(NZ): +64 21 797981 Cell(US): +1 415 515 8636 Email: dave.darling@pelnz.com 9